Khanyukov O. O., Yehudina Ye. D., Sapozhnychenko L. V., Karakay V. L.


About the author:

Khanyukov O. O., Yehudina Ye. D., Sapozhnychenko L. V., Karakay V. L.



Type of article:

Scentific article


This investigation aimed to determine the effectiveness of the drug therapy and lifestyle modification combination in improving the life quality and cardiovascular event prevention in hypertensive patients. The study included 30 patients with stage 2 essential hypertension who received the antihypertensive and lipid-lowering drugs and adhered to recommendations for lifestyle changes (quitting smoking and alcohol drinks, dosed physical exertion, minimizing stress) for 5 years. Before and after 5 years from the treatment onset, EQ-5D-5L survey was conducted, indicating a statistically significant (p˂0.05) improvement in the life quality of reducing discomfort by 40% from baseline, reducing anxiety and depression by 33%, recovery of daily activities by 29%. According to the visual analogue scale, we obtained a significant improvement in the subjective assessment of health status by 25%. The life quality index increased by 19%. According to Non-Laboratory Interheart Risk Score, there was a significant reduction in the cardiovascular complications risk (p˂0.05) by 38% (from 20.4 ± 2.08 (high risk) to 12.7 ± 1.8 (moderate risk) points). On the Cholesterol based Interheart Risk Score scale, there was a significant (p˂0.05) risk reduction by 45% (from 8.2 ± 1.88% (high risk) to 3.7 ± 0.65% (medium risk)). According to the results of our study, antihypertensive and hypolipidemic therapy in combination with the rejection of smoking, metered physical exercises and stress reduction have leaded to decreasing the risk of cardiovascular complications in the next 10 years from high and very high level to moderate level. The prediction of the development of cardiovascular disease complications using non-laboratory tests (NonLaboratory InterHeart Risk Score) provides the same accuracy of calculation as with the Laboratory Based InterHeart Risk Score, which includes laboratory data. According to the EQ-5D-5L questionnaire the participants of this study noted improvement in quality of life due to reducing discomfort and anxiety associated with this disease and resumption the daily activities. According to data of visual analogue scale for assessing the subjective health status, patients noted the significant improvement in their health condition (from 61.2 ± 4.91 to 76.6 ± 3.76 if p <0.05). Study shows that the risk of cardiovascular complications in patients with arterial hypertension is corrected not only by prescribing adequate therapy aimed at supporting the target blood pressure level, correcting the lipid profile, but also by providing recommendations for the lifestyle modification.


arterial hypertension, risk factors, cardiovascular complications, life quality


  1. European Society of Hypertension/European Society of Cardiology. European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. 2018.
  2. Tocci G, Valenti V, Sciarretta S, Volpe M. Multivariate risk assessment and risk score cards in hypertension. Vasc Health Risk Manag. 2007 Jun;3(3):313-20.
  3. Leif RE. Rationale for multiple risk intervention: the need to move from theory to practice. Vasc Health Risk Manag. 2007 Dec;3(6):985-97.
  4. [NCEP] National Cholesterol Education Program. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143-421.
  5. Sever PS, Dahlof B, Poulter NR. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.
  6. Hajjar I, Kochen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199-206.
  7. Joseph P, Yusuf S, Lee SF, Quazi I, Teo K, Rangarajan S, et al. Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. Heart. 2018;104:581-7.
  8. Ministerstvo okhorony zdorovia Ukrainy. Unifikovaniy klinichniy protokol nadannya pervinnoyi, extrenoyi ta vtorinnoyi (specializovanoyi) medichnoyi dopomogy khvorym na arterialnu hypertensiyu, 2012 rik. 2012 Trav;384. [in Ukrainian].
  9. European Society of Hypertension/European Society of Cardiology. European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. 2013.
  10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.
  11. Van den Hoogen PC, Feskens EJ, Nagelkerke NJ. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med. 2000;342:1-8.

Publication of the article:

«Bulletin of problems biology and medicine» Issue 3 (152), 2019 year, 204-209 pages, index UDK 616.12-008.331.4-037-06:616-092.11